[
    [
        {
            "time": "",
            "original_text": "中国生物新冠疫苗提速：已获多国Ⅲ期临床批件，入组超2万人",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "提速",
                    "多国",
                    "Ⅲ期临床",
                    "批件",
                    "入组",
                    "2万人"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "中国生物新冠疫苗提速：已获多国Ⅲ期临床批件，入组超2万人",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]